Filing Flows › Comparisons › ATRA vs PALI
Atara Biotherapeutics vs Palisade Bio: ATRA and PALI compared
Atara Biotherapeutics is the larger company: $630K of revenue in its latest quarter (Q2 2026) against $500K for Palisade Bio (Q2 2026).
Where the money goes: ATRA and PALI
Atara Biotherapeutics (ATRA) · Q2 2026
Atara Biotherapeutics, Q2 2026: revenue $630K (-96% year over year), operating margin -749.2%, net loss $4.8M, operating cash flow −$3.3M. The chart follows the revenue to costs, profit and cash.
Palisade Bio (PALI) · Q2 2026
Palisade Bio, Q2 2026: revenue $500K, net loss $10.6M, operating cash flow −$7.6M. The chart follows the revenue to costs, profit and cash.
| Atara Biotherapeutics (ATRA) | Palisade Bio (PALI) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $630K | $500K |
| Revenue growth, Y/Y | -96% | — |
| Operating margin | -749.2% | n/m |
| Net earnings | −$4.8M | −$10.6M |
| Net margin | -767.3% | — |
| Operating cash flow | −$3.3M | −$7.6M |
Questions
Which is bigger, Atara Biotherapeutics or Palisade Bio?
Atara Biotherapeutics is the larger company: $630K of revenue in its latest quarter (Q2 2026) against $500K for Palisade Bio (Q2 2026).
More: Atara Biotherapeutics earnings · how Atara Biotherapeutics makes money · Palisade Bio earnings · how Palisade Bio makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 12, 2026; 10-Q filed Aug 10, 2026). Fiscal quarters can end on different dates. Not investment advice.